Posted by Michael Wonder on 28 Sep 2023
FDA approves bosutinib for paediatric patients with chronic myelogenous leukaemia
26 September 2023 - Today, the FDA approved bosutinib (Bosulif, Pfizer) for paediatric patients 1 year of age and older with chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia that is newly diagnosed or resistant or intolerant to prior therapy.
The FDA also approved a new capsule dosage form available in strengths of 50 mg and 100 mg.
